Published on

Medicine – Acute Myeloid Leukaemia (AML)

Acute myeloid leukaemia (AML) is an aggressive haematological malignancy characterised by the clonal proliferation of immature myeloid precursor cells (myeloblasts) in the bone marrow, peripheral blood and occasionally other tissues.

The accumulation of abnormal myeloblasts suppresses normal haematopoiesis, resulting in bone marrow failure, while infiltration of extramedullary tissues may produce additional clinical manifestations.

AML predominantly affects adults, particularly older adults, and generally requires urgent specialist assessment and treatment.

Important Clinical Principle

AML commonly presents with anaemia, infections and bleeding due to bone marrow failure. The presence of Auer rods in circulating blasts strongly supports myeloid differentiation, although Auer rods are not present in every case.

1. Epidemiology

  • AML is the most common acute leukaemia in adults.
  • The median age at diagnosis is approximately 68–70 years in many populations.
  • Incidence increases with age.
  • AML may arise de novo or develop following myelodysplastic syndromes, other myeloid neoplasms or previous cytotoxic treatment.

2. Pathophysiology

AML results from acquired genetic and epigenetic abnormalities in haematopoietic precursor cells.

These abnormalities impair normal myeloid differentiation and promote abnormal proliferation and survival.

Pathophysiology Flowchart

Acquired Genetic Abnormalities Myeloid precursor cells Uncontrolled Myeloblast Proliferation Bone Marrow Replacement Suppression of normal haematopoiesis Bone Marrow Failure Anaemia / Infections / Bleeding Possible Extramedullary Infiltration Potentially life-threatening disease

3. Clinical Features

AML commonly presents with manifestations of bone marrow failure or leukaemic infiltration.

A. Bone Marrow Failure

Abnormality Clinical Manifestations
AnaemiaFatigue, pallor, weakness, dyspnoea
NeutropeniaFever, recurrent or severe infections
ThrombocytopeniaEasy bruising, petechiae, epistaxis, gum bleeding
Severe marrow dysfunctionPancytopenia and life-threatening complications

B. Fever and Infection

Fever may arise from infection associated with neutropenia or from the leukaemic disease itself.

Common presentations include:

  • Bacterial infections.
  • Pneumonia.
  • Oral infections.
  • Sepsis.
Medical Emergency: Febrile neutropenia requires prompt assessment and empiric antimicrobial treatment.

C. Bleeding and Disseminated Intravascular Coagulation (DIC)

Bleeding may occur due to thrombocytopenia and, in some patients, coagulation abnormalities.

Acute promyelocytic leukaemia (APL) is particularly associated with severe coagulopathy, including DIC and hyperfibrinolysis.

Manifestations may include:

  • Petechiae and purpura.
  • Epistaxis and gum bleeding.
  • Gastrointestinal bleeding.
  • Intracranial haemorrhage in severe cases.

D. Hepatosplenomegaly

Hepatomegaly and splenomegaly may occur due to leukaemic infiltration.

Lymphadenopathy is less prominent than in acute lymphoblastic leukaemia but can occur.

E. Gingival Infiltration

Leukaemic infiltration of the gums can produce gingival enlargement or hypertrophy.

This is particularly associated with AML showing monocytic differentiation.

F. Orbital and Other Extramedullary Infiltration

AML may produce extramedullary tumours known as myeloid sarcomas.

Possible sites include:

  • Orbit.
  • Skin (leukaemia cutis).
  • Gingiva.
  • Lymph nodes.
  • Bone and soft tissues.
  • Central nervous system, less commonly.

Orbital infiltration may present with proptosis or visual disturbance.

G. Hyperleukocytosis and Leukostasis

Markedly elevated circulating blast counts may impair microvascular circulation.

Possible manifestations include:

  • Dyspnoea and hypoxaemia.
  • Headache.
  • Confusion.
  • Visual disturbances.
  • Neurological deficits.

Leukostasis is a life-threatening complication requiring urgent specialist management.

4. Peripheral Blood Film

The peripheral blood film may demonstrate circulating myeloblasts, sometimes containing Auer rods.

Auer Rods

Auer rods are needle-shaped, reddish-purple cytoplasmic inclusions formed from fused primary azurophilic granules.

They support myeloid differentiation and are an important diagnostic clue.

Auer Rod Schematic

Auer rod Nucleus Cytoplasm Myeloblast with Auer Rod

Simplified educational illustration; not an actual blood film.

Examination Pearl: Auer rods are characteristic of certain AML subtypes but are not present in every case. Their absence does not exclude AML.

5. Diagnosis and Investigations

A. Full Blood Count

Possible findings include:

  • Anaemia.
  • Thrombocytopenia.
  • Elevated, normal or reduced white cell count.
  • Circulating blasts.

B. Bone Marrow Examination

Bone marrow aspiration and trephine biopsy assess blast burden, morphology and marrow architecture.

Traditionally, AML was diagnosed when myeloblasts represented at least 20% of nucleated cells in blood or marrow.

However, current classifications recognise certain genetically defined AML entities that can be diagnosed below the traditional 20% threshold. Specific requirements vary between classification systems.

C. Flow Cytometry and Immunophenotyping

Common myeloid markers include:

  • CD13.
  • CD33.
  • CD117.
  • Myeloperoxidase (MPO).
  • CD34, expressed in many but not all AML cases.

The exact immunophenotype varies by AML subtype.

D. Cytogenetic and Molecular Testing

Genetic analysis is essential for classification, prognosis and treatment selection.

Genetic Abnormality Clinical Significance
PML::RARA, t(15;17)Acute promyelocytic leukaemia
RUNX1::RUNX1T1, t(8;21)Core-binding factor AML
CBFB::MYH11, inv(16)Core-binding factor AML
NPM1 mutationDefines an important molecular AML subgroup
FLT3 mutationInfluences risk assessment and targeted treatment
CEBPA mutationCertain bZIP mutations define a favourable-risk subgroup
TP53 mutationOften associated with adverse-risk disease

E. Other Investigations

  • Coagulation profile, including PT, aPTT, fibrinogen and D-dimer.
  • Renal function and electrolytes.
  • Liver function.
  • LDH and uric acid.
  • Blood cultures when infection is suspected.
  • Baseline cardiac assessment before anthracycline-based chemotherapy when indicated.

Diagnostic Flowchart

Suspected AML Anaemia / infection / bleeding Blood Count and Blood Film Blasts ± Auer rods Bone Marrow Examination Morphology / blast assessment Immunophenotyping Cytogenetic / molecular testing Risk-Based Treatment Planning Subtype / genetic risk / patient fitness Urgent supportive care as required

6. Important AML Subtype: Acute Promyelocytic Leukaemia (APL)

Acute promyelocytic leukaemia (APL) is a distinct subtype of AML characterised by the PML::RARA fusion, usually caused by t(15;17).

APL is particularly important because of its association with severe, potentially fatal bleeding.

APL Is a Haematological Emergency

When APL is suspected, all-trans retinoic acid (ATRA) should be started immediately under specialist direction, without waiting for genetic confirmation, alongside urgent management of coagulopathy.

Characteristic Features of APL

  • PML::RARA fusion gene.
  • Abnormal promyelocytes.
  • Possible bundles of Auer rods (“faggot cells”).
  • Severe bleeding tendency.
  • DIC and hyperfibrinolysis.

Treatment of APL

APL is commonly treated with:

  • ATRA: All-trans retinoic acid.
  • Arsenic trioxide (ATO).
  • Additional treatment according to risk and clinical circumstances.
  • Urgent blood product support and correction of coagulopathy.

7. Treatment of AML

Treatment depends on age, fitness, AML subtype, genetic risk and patient preferences.

A. Intensive Chemotherapy

Fit patients with appropriate AML subtypes may receive induction chemotherapy to achieve remission.

A traditional regimen is 7+3 chemotherapy:

  • Cytarabine: Administered for seven days.
  • Anthracycline: Such as daunorubicin or idarubicin, administered for three days.

Targeted agents may be added when indicated by molecular findings.

B. Consolidation Therapy

After remission, further treatment aims to eliminate residual leukaemic cells and reduce relapse risk.

Options include:

  • High-dose cytarabine-based chemotherapy.
  • Allogeneic haematopoietic stem cell transplantation in selected patients.

C. Lower-Intensity Treatment

For patients unsuitable for intensive chemotherapy, options may include:

  • Azacitidine plus venetoclax.
  • Decitabine-based regimens.
  • Other lower-intensity or targeted treatments according to AML subtype and clinical circumstances.

D. Targeted Therapy

Examples include:

  • FLT3 inhibitors for eligible FLT3-mutated AML.
  • IDH inhibitors in selected IDH-mutated AML.
  • Other molecularly targeted treatments according to disease characteristics and availability.

E. Stem Cell Transplantation

Allogeneic haematopoietic stem cell transplantation can provide potentially curative treatment for selected patients, particularly those with higher-risk disease or relapse.

Transplant decisions depend on relapse risk, treatment response, comorbidities and donor availability.

F. Supportive Care

  • Red cell and platelet transfusions when indicated.
  • Prompt treatment of infections.
  • Prevention and management of tumour lysis syndrome.
  • Management of DIC and bleeding.
  • Antimicrobial prophylaxis in selected patients.
  • Fertility preservation counselling when appropriate.

Treatment Flowchart

Confirmed AML Subtype, genetics and fitness Fit for Intensive Treatment Not Fit for Intensive Treatment Intensive Induction Cytarabine + anthracycline ± targeted agents Assess remission Lower-Intensity Therapy Azacitidine + venetoclax or other suitable regimen Assess response Response-Adapted Management Consolidation / transplant / ongoing therapy

Simplified general AML pathway. APL follows a distinct urgent treatment pathway.

8. Prognosis

AML prognosis varies considerably according to:

  • Age and performance status.
  • Cytogenetic and molecular abnormalities.
  • AML subtype.
  • Response to treatment.
  • Measurable residual disease (MRD).
  • Eligibility for transplantation.

Older teaching materials sometimes quote an overall cure rate of approximately 30%, but this is not a reliable universal figure for contemporary AML.

Some younger patients with favourable-risk AML have substantially better outcomes, whereas older or adverse-risk patients may have poorer outcomes.

9. AML vs ALL

Feature AML ALL
Cell lineageMyeloid precursorsLymphoid precursors
Typical populationPredominantly adultsCommon in children; also occurs in adults
Auer rodsMay be presentAbsent
MPOOften positiveUsually negative
Gingival infiltrationParticularly associated with monocytic AMLLess characteristic
CNS involvementLess common at presentationMore clinically prominent in some subtypes
Main treatmentChemotherapy, targeted agents ± transplantMulti-agent chemotherapy, immunotherapy ± transplant

10. High-Yield Examination Summary

Feature Key Point
DiseaseAggressive myeloid malignancy
Typical populationAdults, especially older adults
Main mechanismMyeloblast proliferation and marrow failure
Clinical featuresFever, anaemia, infection, bleeding
Blood filmMyeloblasts ± Auer rods
Diagnostic investigationsBone marrow, flow cytometry, cytogenetics and molecular testing
Traditional blast threshold≥20%, with genetic exceptions
Gingival infiltrationAssociated with monocytic AML
Orbital infiltrationMay represent myeloid sarcoma
DIC associationParticularly acute promyelocytic leukaemia
APL genetic hallmarkPML::RARA, usually t(15;17)
APL emergency treatmentImmediate ATRA when suspected
Intensive treatmentCytarabine plus anthracycline-based induction
Lower-intensity optionAzacitidine plus venetoclax
Potentially curative procedureAllogeneic stem cell transplantation
PrognosisHighly variable according to risk and response

11. Key Examination Pearls

  • AML is the most common acute leukaemia in adults.
  • Bone marrow failure produces anaemia, infection and bleeding.
  • Auer rods support a diagnosis of myeloid leukaemia but are not always present.
  • Gingival hypertrophy is classically associated with AML with monocytic differentiation.
  • Orbital infiltration may occur as myeloid sarcoma.
  • APL is associated with PML::RARA and severe coagulopathy.
  • Suspected APL requires immediate ATRA and urgent specialist management.
  • Bone marrow examination, immunophenotyping and molecular testing are essential.
  • Intensive induction chemotherapy commonly uses cytarabine and an anthracycline.
  • Allogeneic stem cell transplantation is considered for selected patients.
  • Prognosis depends strongly on genetic risk and treatment response.
Most Important Examination Point

An adult presenting with fever, pallor, recurrent infections, bruising or bleeding, together with circulating myeloblasts and Auer rods, should raise suspicion of acute myeloid leukaemia.

Critical Emergency

AML with DIC, particularly suspected acute promyelocytic leukaemia, requires immediate specialist treatment because life-threatening haemorrhage may occur before definitive diagnostic confirmation.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments